---
layout: default
title: Iron
parent: 僅模型預測 (L5)
nav_order: 179
evidence_level: L5
indication_count: 6
---

# Iron
{: .fs-9 }

證據等級: **L5** | 預測適應症: **6** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Using the drug-repurposing evaluation report template to generate this report directly from the supplied Evidence Pack (no coding skill applies here — this is a document-generation task).

# Iron: From Iron Deficiency to Vitamin B12- and Folate-Independent Constitutional Megaloblastic Anemia

## One-Sentence Summary

Iron (DrugBank DB01592) is an essential trace mineral conventionally used as replacement therapy for iron-deficiency states; detailed original-indication and mechanism-of-action data are not yet available in this evidence pack.
The TxGNN model's top-ranked prediction is **vitamin B12- and folate-independent constitutional megaloblastic anemia**, with a **99.89% prediction score**, but **zero clinical trials and zero publications** currently support this specific direction — the model's own rationale flags a mechanistic contradiction.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented (drug not marketed in New Zealand; no license/label data available) |
| Predicted New Indication | Vitamin B12- and folate-independent constitutional megaloblastic anemia |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 |
| New Zealand Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known pharmacology, iron is an essential trace mineral required for hemoglobin synthesis and oxygen transport; it is conventionally used as replacement therapy for iron-deficiency states, which classically present as **microcytic, hypochromic anemia**.

The predicted indication here — vitamin B12- and folate-independent constitutional megaloblastic anemia — is defined precisely by the *opposite* red-cell morphology (macrocytic) and arises from inherited defects in DNA synthesis pathways (e.g., TRMA, congenital dyserythropoietic anemia), not from iron deficiency. The evidence pack's own repurposing rationale is explicit on this point: "iron supplementation lacks reasonable biological justification" for this indication, and the high TxGNN score most likely reflects semantic proximity between "anemia" concepts in the knowledge graph rather than a genuine mechanistic link.

For this reason, the mechanistic rationale for the #1-ranked prediction does not support further investment, despite the numerically high model confidence score. Note that this same evidence pack contains other iron-related predictions with materially stronger mechanistic and evidentiary support (see Conclusion), which may be more productive directions to pursue.

## Clinical Trial Evidence

Currently no related clinical trials registered

## Literature Evidence

Currently no related literature available

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction has no supporting clinical trials or literature (Evidence Level L5, model prediction only), and the model's own mechanistic rationale indicates the underlying biology (iron deficiency → microcytic anemia) runs counter to the pathophysiology of the predicted indication (a macrocytic, DNA-synthesis-defect anemia). There is no basis to advance this specific candidate.

**To proceed, the following is needed:**
- TFDA/label safety data (warnings, contraindications) — currently a Blocking data gap preventing any S1 safety review
- Verified mechanism of action (MOA) data from DrugBank — currently a High-severity data gap affecting mechanistic-relevance analysis
- If pursuing iron repurposing further, consider redirecting evaluation effort toward the other candidates in this same evidence pack with stronger support: **Plummer-Vinson syndrome** (rank 2, Evidence Level L3, 19 literature citations, direct and well-established mechanistic link to iron deficiency) and **vitamin deficiency disorder** (rank 5, Evidence Level L1, multiple completed Phase 3/4 RCTs, "Proceed with Guardrails" recommendation) — both are mechanistically coherent with iron's known pharmacology, unlike the current top-ranked candidate
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

